Slide 1: Third Quarter 2024 Operating & Financial Results Conference Call / Webinar
Third Quarter 2024 Operating & Financial Results Conference Call / Webinar November 7th , 2024 4:30 PM Eastern Time NASDAQ :LTRN
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements r
Slide 3: Contents and Speakers
Contents Speakers Panna Sharma David Margrave Kishor Bhatia CEO and President CFO CSO 01 Introduction 02 2024 Q3 Highlights 03 Financial Highlights 04 Clinical Trial Updates 05 HarmonicTM Updates in Asia 06 Key R&D Initiatives
Slide 4: 3rd Quarter Highlights 1 of 3
2024 ü Lantern is advancing three AI-guided precision-oncology 3rd Quarter drug candidates in active Phase 1 and Phase 2 clinical trials, while evaluating additional ADC-based preclinical Highlights molecules for development. ü Preliminary patient data and clinical readouts for the 1of 3 Phase 2 LP-
Slide 5: 3rd Quarter Highlights 2 of 3
2024 ü Phase 1 clinical trials for both synthetic lethal drug 3rd Quarter candidates, LP-184 and LP-284, continue to advance with no dose-limiting toxicities observed in any of the patient cohorts enrolled and over 50 patients dosed to-date Highlights across both trials*. ü LP-184, which will be dev
Slide 6: 3rd Quarter Highlights 3 of 3
Biomarker analysis for PTGR1 expression using qPCR for the 2024 ü first 7 cohorts of patients enrolled in the Phase 1a LP-184 clinical trial has begun, and will help guide the advancement 3rd Quarter of PTGR1 as a key RNA biomarker that can guide patient response prediction. Highlights ü Three U.S.
Slide 7: Financial Updates Q3 2024
Financial Updates Q3 2024 Summary Results of Operations Balance Sheet Highlights & Summary Three Months Ended September 30, (unaudited) 09/30/2024 12/31/2023 2024 2023 (unaudited) Operating expenses: Cash, Cash Equivalents & $ 28,053,765 $ 41,302,672 Marketable Securities General and administrative
Slide 8: Lantern's diverse & unique AI-driven pipeline of drug programs
Lantern’s diverse & unique AI-driven pipeline of 11 drug programs including RADR® collaborations and Starlight Therapeutics Lantern Pharma (NASDAQ: LTRN) Orphan Rare Pediatric Lead Candidate Indication Discovery Preclinical Phase I Phase II Designation Disease Non-Small Cell Lung Cancer LP-300 for N
Slide 9: Starlight's pipeline focused on multiple CNS indications
Starlight’s pipeline is focused on multiple CNS indications in both adult and pediatric patients Starlight Therapeutics ADULT CNS CANCERS Orphan Rare Pediatric Lead Candidate Indication Discovery Preclinical Phase I Phase II Designation Disease Glioblastoma (GBM)* STAR-001 Brain Metastases (TNBC)**
Slide 10: LP-184 & LP-284 advance with no dose-limiting toxicities
Synthetic lethal drug candidates, LP-184 & LP-284, continue to advance with no dose-limiting toxicities observed in any of the patient cohorts First-In-Human Trial for LP-184 Clinicaltrials.gov (NCT05933265) • Trial launched and multiple US sites activated, including Fox Chase Cancer Center • Cohort
Slide 11: Eleven FDA designations demonstrate our data-driven, AI-enabled approach
Eleven FDA designations demonstrate our data-driven, AI-enabled approach to transformative drug development & strengthen our commercial value Designation Candidate Indication Date Fast Track Designation LP-184 Glioblastoma Sep. 2024 LP-184 Pancreatic Cancer Aug. 2021 LP-184 Glioblastoma Aug. 2021 Or
Slide 12: The Harmonic Phase 2 trial for LP-300
The HarmonicTM Phase 2 trial for LP-300 Accelerating recruitment efforts for a growing indication with limited treatment options Global NCT05456256 Phase 2 Multi-Site in US & Asia Trial Design Trial Updates 60 Patients will receive LP-300 with pemetrexed and carboplatin* • Preliminary patient data a
Slide 13: Expanding the Phase 2 clinical trial to East Asia
Expanding the phase 2 clinical trial to east Asia: boosting patient enrollment in countries with high incidences of NSCLC in never smokers Highlights of all lung cancer • Study expansion to Taiwan and Japan with 5 sites patients in East Asia in each country are never smokers* • All 10 sites to be ac
Slide 14: Advancing LP-184: identifying the best combination agents
Advancing the development of enhanced durability and efficacy of responses with LP-184: identifying the best combination agents • Combination therapies can further expand clinical opportunities and increase the therapeutic window of success • Understanding how best to leverage Mechanism of Action an
Slide 15: LP-184 and olaparib combination achieves greater tumor regression
LP-184 and olaparib combination achieves 3 to 14-fold greater tumor regression compared to olaparib alone in TNBC PDX models Efficacious tumor regression is achieved using 5x lower doses of LP-184 in combination as compared to doses used as monotherapy Tumor Volume in HBCx-10 PARPi sensitive TNBC PD
Slide 16: LP-184 can combat PARPi resistance
LP-184 can combat PARPi resistance LP-184 is not a substrate of major ABC transporters A BRCA2 reversion mutant xenograft model responded to LP-184 Loss of 53BP1-Shieldin confers sensitivity to LP-184 Key Insights • Inactivation of SLFN11 is a predictive biomarker for PARPi resistance and resistance
Slide 17: Spironolactone and LP-184 enhance efficacy in glioblastoma in vitro
Combination of spironolactone and LP-184 enhances anti-tumor efficacy in glioblastoma in vitro Treatment of GBM cells with Spironolactone 24h before LP-184 led to…. 3x increase in γH2AX DNA Depletion of ERCC3 protein by A 3-6x increase in LP-184 sensitivity B C up to 95% damage response to LP-184 SP
Slide 18: Spironolactone and LP-184 enhance efficacy in glioblastoma in vivo
Combination of spironolactone and LP-184 enhances anti-tumor efficacy in glioblastoma in vivo Complete tumor regression with prolonged duration of response • Spironolactone monotherapy had no effect on tumor growth compared with vehicle- treated controls in U87 subcutaneous xenografts • Spironolacto
Slide 19: Administering spironolactone with LP-184 in GBM trials: timing insights
Clinical practices for administering spironolactone with LP-184 in GBM trials: timing insights for optimal efficacy Western blot shows kinetics of ERCC3 degradation and recovery reaching a maximum of 70% protein level depletion at 8 hours post administration • To optimize the administration of Spiro
Slide 20: LP-184 induces replication stress response defect in TNBC cells
LP-184 induces replication stress response defect similar to cell cycle checkpoint inhibitors in TNBC Cells Cell Cycle Analysis of BT20 TNBC Cells Treated with LP-184 and CHKi Prexasertib 1. Induction of replication stress response defects (RSRD) has been shown to enhance sensitivity to anti-PD-1 th
Slide 21: LP-184 anti-tumor efficacy in mouse TNBC models with anti-PD1
LP-184 demonstrates anti-tumor efficacy in mouse TNBC models and potential to sensitize tumors non-responsive to anti-PD1 therapy T11 mouse TNBC tumors treated with LP-184 and anti-PD1 antibody (A) (B) Tumor volume (mm3) Treatment arm Day 22 TGI Anti-PD1 (10mg/kg) 17% Treatment Days LP-184 (4mg/kg)
Slide 22: LP-184 reshaped the tumor microenvironment with ICB therapy
LP-184 reshaped the tumor microenvironment by decreasing M2 macrophages (Pro-Antitumor profile) and increased T cell infiltration and T cell function when combined with ICB therapy Model of cold and hot tumor microenvironment of mouse TNBC tumors Relative to vehicle treatment: • LP-184 decreased M2
Slide 23: Lantern Pharma 2024 webinar series – Webinar Wednesdays
Lantern Pharma 2024 webinar series – Webinar Wednesdays – featuring world-class collaborators and researchers July Webinar Wednesday August Webinar Wednesday September Webinar Wednesday Starlight Therapeutics – Born from AI, Harmonic Phase 2 Clinical Trial for Never Childhood Cancer Awareness Month
Slide 24: Publications highlighting the clinical value of RADR insights
Publications highlighting the clinical value of RADR® insights & de-risking the development of Lantern’s drug candidates PUBLICATION | PLOS ONE JOURNAL Expanding the repertoire of Antibody Drug Conjugate (ADC) targets with improved tumor selectivity and range of potent payloads through in-silico ana
Slide 25: 2024-25 Objectives
2024-25 Objectives A Breakthrough Year for Lantern ● Complete Phase 1a clinical trial for LP-184; commence Phase 1b and investigator led trial(s) T ● Accelerate enrollment in first-in-human clinical trial for LP-284 in NHL + other cancers O ● Commence enrollment of The HarmonicTM Trial in targeted s
Slide 26: IR Contact
IR Contact: IR@lanternpharma.com 1-972-277-1136 NASDAQ: LTRN www.lanternpharma.com CONNECT WITH US @LanternPharma linkedin.com/company/lanternpharma